vs
Side-by-side financial comparison of AGIOS PHARMACEUTICALS, INC. (AGIO) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
AGIOS PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($20.0M vs $18.7M, roughly 1.1× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -541.1%, a 540.3% gap on every dollar of revenue. On growth, AGIOS PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (86.1% vs -25.7%). CytomX Therapeutics, Inc. produced more free cash flow last quarter ($-15.8M vs $-97.3M). Over the past eight quarters, AGIOS PHARMACEUTICALS, INC.'s revenue compounded faster (56.1% CAGR vs -15.9%).
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
AGIO vs CTMX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.0M | $18.7M |
| Net Profit | $-108.0M | $-154.0K |
| Gross Margin | 90.6% | — |
| Operating Margin | -608.9% | -6.9% |
| Net Margin | -541.1% | -0.8% |
| Revenue YoY | 86.1% | -25.7% |
| Net Profit YoY | -11.9% | 97.6% |
| EPS (diluted) | $-1.86 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.0M | — | ||
| Q3 25 | $12.9M | — | ||
| Q2 25 | $12.5M | $18.7M | ||
| Q1 25 | $8.7M | $50.9M | ||
| Q4 24 | $10.7M | $38.1M | ||
| Q3 24 | $9.0M | $33.4M | ||
| Q2 24 | $8.6M | $25.1M | ||
| Q1 24 | $8.2M | $41.5M |
| Q4 25 | $-108.0M | — | ||
| Q3 25 | $-103.4M | — | ||
| Q2 25 | $-112.0M | $-154.0K | ||
| Q1 25 | $-89.3M | $23.5M | ||
| Q4 24 | $-96.5M | $18.9M | ||
| Q3 24 | $947.9M | $5.7M | ||
| Q2 24 | $-96.1M | $-6.5M | ||
| Q1 24 | $-81.5M | $13.8M |
| Q4 25 | 90.6% | — | ||
| Q3 25 | 87.0% | — | ||
| Q2 25 | 86.3% | — | ||
| Q1 25 | 87.6% | — | ||
| Q4 24 | 88.3% | — | ||
| Q3 24 | 91.3% | — | ||
| Q2 24 | 82.6% | — | ||
| Q1 24 | 92.3% | — |
| Q4 25 | -608.9% | — | ||
| Q3 25 | -907.4% | — | ||
| Q2 25 | -1020.1% | -6.9% | ||
| Q1 25 | -1222.0% | 44.4% | ||
| Q4 24 | -1165.3% | 46.4% | ||
| Q3 24 | -1146.9% | 12.3% | ||
| Q2 24 | -1228.3% | -33.7% | ||
| Q1 24 | -1124.3% | 28.1% |
| Q4 25 | -541.1% | — | ||
| Q3 25 | -803.1% | — | ||
| Q2 25 | -899.4% | -0.8% | ||
| Q1 25 | -1023.3% | 46.2% | ||
| Q4 24 | -899.6% | 49.6% | ||
| Q3 24 | 10574.7% | 17.2% | ||
| Q2 24 | -1115.7% | -26.0% | ||
| Q1 24 | -995.8% | 33.3% |
| Q4 25 | $-1.86 | — | ||
| Q3 25 | $-1.78 | — | ||
| Q2 25 | $-1.93 | — | ||
| Q1 25 | $-1.55 | — | ||
| Q4 24 | $-1.44 | — | ||
| Q3 24 | $16.22 | — | ||
| Q2 24 | $-1.69 | — | ||
| Q1 24 | $-1.45 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.1M | $49.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $119.9M |
| Total Assets | $1.3B | $175.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.1M | — | ||
| Q3 25 | $92.7M | — | ||
| Q2 25 | $80.9M | $49.0M | ||
| Q1 25 | $79.0M | $47.6M | ||
| Q4 24 | $76.2M | $38.1M | ||
| Q3 24 | $253.7M | $40.6M | ||
| Q2 24 | $84.5M | $43.2M | ||
| Q1 24 | $118.8M | $36.2M |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.4B | $119.9M | ||
| Q1 25 | $1.5B | $25.0M | ||
| Q4 24 | $1.5B | $-456.0K | ||
| Q3 24 | $1.6B | $-23.5M | ||
| Q2 24 | $660.5M | $-31.2M | ||
| Q1 24 | $743.9M | $-31.7M |
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.5B | $175.1M | ||
| Q1 25 | $1.6B | $98.5M | ||
| Q4 24 | $1.7B | $120.5M | ||
| Q3 24 | $1.8B | $139.0M | ||
| Q2 24 | $773.1M | $159.2M | ||
| Q1 24 | $849.7M | $184.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-96.2M | $-15.8M |
| Free Cash FlowOCF − Capex | $-97.3M | $-15.8M |
| FCF MarginFCF / Revenue | -487.5% | -84.6% |
| Capex IntensityCapex / Revenue | 5.6% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-377.3M | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-96.2M | — | ||
| Q3 25 | $-88.2M | — | ||
| Q2 25 | $-77.1M | $-15.8M | ||
| Q1 25 | $-111.5M | $-21.0M | ||
| Q4 24 | $-133.2M | $-19.9M | ||
| Q3 24 | $-84.2M | $-20.7M | ||
| Q2 24 | $-72.6M | $-19.5M | ||
| Q1 24 | $-99.9M | $-26.0M |
| Q4 25 | $-97.3M | — | ||
| Q3 25 | $-89.7M | — | ||
| Q2 25 | $-78.0M | $-15.8M | ||
| Q1 25 | $-112.3M | $-21.2M | ||
| Q4 24 | $-134.1M | $-20.0M | ||
| Q3 24 | $-84.6M | $-20.7M | ||
| Q2 24 | $-72.7M | $-19.6M | ||
| Q1 24 | $-100.0M | $-26.2M |
| Q4 25 | -487.5% | — | ||
| Q3 25 | -696.5% | — | ||
| Q2 25 | -626.2% | -84.6% | ||
| Q1 25 | -1286.4% | -41.6% | ||
| Q4 24 | -1250.1% | -52.5% | ||
| Q3 24 | -944.2% | -62.1% | ||
| Q2 24 | -844.4% | -78.2% | ||
| Q1 24 | -1221.2% | -63.1% |
| Q4 25 | 5.6% | — | ||
| Q3 25 | 12.1% | — | ||
| Q2 25 | 7.0% | 0.1% | ||
| Q1 25 | 8.8% | 0.2% | ||
| Q4 24 | 9.0% | 0.2% | ||
| Q3 24 | 4.7% | 0.1% | ||
| Q2 24 | 1.8% | 0.4% | ||
| Q1 24 | 1.7% | 0.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.89× | ||
| Q4 24 | — | -1.05× | ||
| Q3 24 | -0.09× | -3.61× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -1.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AGIO
Segment breakdown not available.
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
